An unmet need is a gap between what people require and what’s currently available to them. The term shows up across medicine, business, and public health, and while the specifics change depending on the field, the core idea stays the same: something important is missing, and the absence has real consequences. Understanding what counts as an unmet need matters because it drives everything from which drugs get fast-tracked to market, to which products companies develop, to how governments allocate healthcare funding.
The Medical Definition
In medicine, an unmet need refers to a condition whose treatment or diagnosis isn’t adequately addressed by existing options. The FDA defines it as including both an immediate need for a specific group of patients (such as treating a serious condition with no available therapy) and a longer-term need for society as a whole, like developing new antibiotics as bacteria grow resistant to current ones.
The simplest case is when no treatment exists at all. About 95% of the roughly 7,000 known rare diseases have no approved treatment, making them some of the clearest examples of unmet medical need in the world. But unmet need doesn’t disappear just because a treatment is on the market. Even when therapies exist, the FDA recognizes several situations where the need remains unmet:
- The treatment doesn’t work for everyone. Some patients fail to respond to available therapies or can’t tolerate their side effects.
- Serious outcomes aren’t addressed. A drug might manage symptoms without affecting the underlying progression of a disease.
- Side effects force people to stop treatment. If toxicity is common enough that patients regularly discontinue therapy for a serious condition, that’s a gap.
- Drug interactions limit options. When available treatments can’t be safely combined with other critical medications a patient needs, the need is still unmet.
- An emerging public health threat arises. Drug shortages or new infectious disease outbreaks create unmet needs even in areas where treatments previously existed.
The European Medicines Agency uses a similar but slightly broader definition. Under EU regulations, an unmet medical need exists when there’s no satisfactory method of diagnosis, prevention, or treatment available, or when a new medicine would offer a “major therapeutic advantage” to affected patients. That language around therapeutic advantage gives European regulators flexibility to consider quality-of-life improvements, not just clinical endpoints.
Why It Matters for Drug Approval
Unmet need isn’t just an abstract concept in medicine. It’s a regulatory gateway. The FDA’s Fast Track designation, which speeds up the review process for new drugs, requires that a therapy fill an unmet medical need. In practice, this means showing that no current therapy exists for the condition, or demonstrating a clear advantage over what’s available. Those advantages can include better effectiveness, fewer serious side effects, improved diagnosis that leads to better outcomes, or the ability to address an emerging public health crisis.
Breakthrough Therapy designation, Accelerated Approval, and Priority Review all hinge on similar logic. A drug company applying for any of these expedited pathways has to make the case that patients are currently underserved. This system creates a direct financial incentive for pharmaceutical companies to pursue treatments for conditions where patients have the fewest options, which is one reason rare disease drug development has accelerated over the past two decades despite the small patient populations involved.
There’s also a less obvious scenario the FDA accounts for. If the only approved treatment for a condition was itself granted accelerated approval based on a surrogate marker (like tumor shrinkage rather than survival), and no one has yet confirmed that the drug actually delivers a meaningful clinical benefit, the FDA still considers that need unmet. In other words, a treatment that exists on paper but hasn’t been proven to help patients in the ways that matter most doesn’t close the gap.
Unmet Needs Beyond the Clinic
Patients often experience unmet needs that don’t show up in clinical trial data. These are the burdens of living with a condition day to day: the inconvenience of treatments that require frequent hospital visits, the pain of injections when an oral medication would work, the mental and emotional toll of managing a complex regimen. Patient-reported outcomes capture some of this by asking people directly about their symptoms, their satisfaction with care, and how disease or treatment affects their physical, mental, emotional, and social well-being. A drug that works just as well as an existing option but comes in a form patients can take at home instead of in an infusion center addresses a real unmet need, even if the clinical outcomes look identical on paper.
The Public Health Perspective
In public health, unmet needs often have less to do with whether a treatment exists and more to do with whether people can actually access it. The Centers for Medicare and Medicaid Services identifies several social factors that create these gaps. People without financial stability may skip preventive care, delay treatment, or go without prescription medications. People without reliable transportation miss appointments. People living in food deserts, neighborhoods without grocery stores that stock fresh produce, face higher risks of heart disease, diabetes, and obesity simply because of where they live.
These aren’t theoretical problems. They create measurable differences in health outcomes across communities. Someone living in an area with high air pollution is more likely to develop respiratory conditions like asthma or COPD. Someone without stable housing may cycle in and out of emergency rooms for conditions that could have been managed with routine outpatient care. The treatment for their condition technically exists, but the practical barriers make it functionally unavailable. That’s an unmet need in every meaningful sense.
Measuring these needs is harder than it sounds. The WHO has noted there’s no standard agreed-upon definition or measure of unmet health need across populations. Most studies rely on self-reported survey data, asking people whether there was a time they needed healthcare and didn’t receive it. Researchers have explored more sophisticated statistical approaches, but the field still lacks a universal measurement framework.
Unmet Needs in Business
Outside of healthcare, the term takes on a commercial meaning. An unmet consumer need is the gap between what products and services currently exist and what people actually want or require. Sometimes customers can articulate what’s missing. More often, they can’t, which is why companies invest heavily in tools to uncover these gaps indirectly.
Businesses identify unmet needs through several approaches. Customer satisfaction surveys generate quantitative data, while open-ended feedback reveals qualitative frustrations. Social listening tools track what people complain about or wish for online. Behavioral analytics show where users abandon a process or struggle with a product. Market segmentation breaks audiences into groups with shared characteristics, making it easier to spot needs that affect specific populations rather than everyone. Journey mapping traces the full experience a customer has with a product or service, highlighting friction points that represent opportunities.
Once a potential unmet need is identified, companies typically validate it before committing resources. Minimum viable products and pilot programs test whether the gap is real and whether a proposed solution resonates. A/B testing lets companies compare new features against existing ones using actual user behavior rather than assumptions. Design thinking workshops sometimes involve customers directly in co-creating solutions, which can surface needs that traditional research methods miss entirely.
The business concept and the medical concept share the same underlying logic. In both cases, the goal is to identify where current options fall short and to understand what “better” would actually look like for the people affected. The difference is mainly in the stakes: in business, an unmet need is a market opportunity; in medicine, it can be the difference between life and death.